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Objective: To clarify the clinical features of pulmonary cryptococcosis in Japanese 
non-HIV population.  
Methods: Retrospective investigation of 151 pulmonary cryptococcosis cases between 
1977 and 2012 was executed. The underlying disease (UDs), aggravating factors, 
radiological characteristics, and treatment were examined.  
Results: Sixty-seven patients (44.4%) had no UDs. The common UDs were diabetes 
(32.1%) followed by hematologic disease (22.6%), and collagen disease (22.6%). 
Peripherally distributed pulmonary nodules/masses were most commonly seen. Lesions 
in the right middle lobe (p = 0.01) and air bronchogram (P=0.05) were significantly 
more frequent, respectively, in patients with UDs than patients without them. Azoles 
were mainly selected for the patients without meningoencephalitis. Mean treatment 
duration for patients with and without UDs was 6.64 and 2.87 months, respectively. 
Patients whose pulmonary nodules improved after treatment continued to experience 
gradual reduction of cryptococcosis antigen titers, even if antigen titers were positive at 
the time of treatment cessation. The average time for antigen titers to become negative 
after treatment cessation was 13.1 and 10.7 months for patients with and without UDs, 
respectively. When groups were compared according to the presence of 
meningoencephalitis complications, deaths, and survivals, factors contributing to 
cryptococcosis prognosis included higher age, hypoproteinemia, hypoalbuminemia, 
steroid use, high C-reactive protein levels, and meningoencephalitis complications. 
Conclusions: It is crucial to consider the presence of UDs and meningoencephalitis for 
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the choice of antifungals and treatment duration for cryptococcosis in non-HIV patients. 
Three- and six months- administration of azoles for pulmonary cryptococcosis with or 
without UDs, respectively is reasonable.  
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Cryptococcus neoformans is a nonmycelial, budding encapsulated yeast-like fungus 
found in soil contaminated with pigeon and chicken excreta [1-4]. Inhalation of 
cryptococcal particles from contaminated soil into the lung is considered the usual route 
of human infection [2, 3]. The organism may cause isolated pulmonary infection or 
hematogenous dissemination involving the central nervous system (CNS), bones, and 
skin, mostly depending on the host immunity [2, 3]. Although cryptococcal infection 
can occur in individuals with normal immunity, it most commonly occurs in 
immunocompromised hosts. Predisposing factors are acquired immune deficiency 
syndrome (AIDS) and other causes of impaired T cell–mediated immunity, e.g., 
transplant-related immunosuppression, hematological malignancies, corticosteroid 
administration, and diabetes mellitus [4-6].  
Although the clinical characteristics and natural history of cryptococcosis in HIV 
patients have been described elsewhere due to its large number, those in non-HIV 
patients have rarely been reported [7]. To date, few studies have reported comparative 
data regarding the clinical manifestations, laboratory findings, radiographic findings and 
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survival of patients with pulmonary cryptococcosis in Japan [8]. Additionally, very few 
research comparing clinical manifestation of cryptococcosis between HIV and non-HIV 
patients [9-11].  
In Japan, the number of HIV/AIDS patients is relatively lower compared to those of 
other countries. However, it is increasing recently and over 20,000 of the cumulative 
patients are registered in Japanese government database to date 
(http://www.nih.go.jp/niid/ja/aids-m/aids-iasrd/2274-kj3888.html).  Hence, the study 
of clinical manifestation of cryptococcal diseases in non-HIV background possess high 
impact. We reviewed 151 cryptococcal cases among non-HIV background and 
investigated the clinical features, including clinical manifestations, underlying 
conditions, laboratory findings, radiological features, treatment, survival, and outcomes.  
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Materials and methods  
Patients 
A retrospective cohort study was conducted by reviewing the medical records of 
patients who had been diagnosed with pulmonary cryptococcosis at Nagasaki 
University Hospital and its affiliated hospitals during the 35-year period between 1977 
and 2012. The patients were grouped into 2 populations based on positivity of 
underlying diseases. Definite case of pulmonary cryptococcosis requires isolation or 
detection of Cryptococcus by lung specimen culture and/or by histopathological 
examination, and only definite cases are recruited in this study. This retrospective study 
including analysis and release of clinical data was approved by the ethical committee of 
Nagasaki University Hospital.  
 
Clinical data 
All available patient records were reviewed from the time of cryptococcal diagnosis 
until the patients died or were lost to follow up.  
The data included clinical manifestations, underlying conditions, laboratory findings 
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(age, lymphocyte count, neutrophil count, immunoglobulin, serum protein, serum 
albumin, CD4/8 ratio, CD4 count, C-reactive protein [CRP], cryptococcal serum 
antigen titers) at the timing of diagnosis, radiological findings, treatment, survival, and 
outcome were recorded.  
Eiken Latex® (Eiken Kagaku Co., Tokyo, Japan) was used for the qualitative and 
semi-quantitative detection of the C. neoformans capsular polysaccharide antigen in 
serum and CSF according to the manufacturer’s instructions. 
 
Interpretation of chest CT scans 
The findings of chest CT scans were assessed for 1) the presence and distribution of 
parenchymal lesions, including nodules, masses, and consolidation; 2) the 
characteristics of nodules and masses; and 3) related thoracic abnormalities such as 
pleural effusion and lymphadenopathy according to previous reports [12]. Based on the 
predominant parenchymal findings from the CT scans, the morphological characteristics 
were classified as solitary nodule/mass (type I), multiple nodules/masses (type II), and 
consolidation (type III). In addition, type II was subdivided into distribution in a single 
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lobe (type IIa) and distribution in multiple lobes (type IIb).   
 
Statistical analysis 
We used FREQ, NPAR1WAY, and ANOVA in SAS. The chi-square test was used to 
compare the frequency of categorical variables (e.g., underlying disease, steroid usage). 
Wilcoxon’s test was used to compare age, lymphocyte count, neutrophil count, serum 
protein, serum albumin, CD4/8 ratio, CD4 count, CRP, and cryptococcal serum antigen 
titers. The Eiken Latex® latex agglutination test was used to detect cryptococcal 
polysaccharide. Antigen titers were transformed to the logarithm to the base 2 (Log2[Ag 
+ 1]). Ag (cryptococcal antigen titer) is expressed as 0, 1, 2, 4, … as powers of 2 and Ag 
+ 1 was expressed as Log2(0 + 1) = 0. 
For radiographic analysis, a chi-square test was employed to compare the presence and 
distribution of parenchymal lesions, nodule and mass characteristics except their 
number, and related thoracic abnormalities between the 2 groups. A Cochran-Armitage 
test was used to analyze the differences among 4 groups based on the number of 
nodules and masses, and among 4 morphological types based on the CT classification 
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One hundred fifty-one patients were diagnosed with pulmonary cryptococcosis during 
the 35-year period between 1977 and 2012. Sixty-seven (44.4%) occurred in the 
patients without underlying diseases. Forty-two were men and 25 were women. 
Eighty-four cases (56.6%) were the patients with underlying disease. Thirty-eight were 
men and 46 were women. 
 
Underlying diseases 
Among 84 patients with underlying diseases, diabetes mellitus was most dominant 
(32.1%) followed by hematological diseases including human T-cell leukemia virus 
type-I carrier (22.6%), collagen disease including systemic lupus erythematosus, 
rheumatoid arthritis and others (22.6%), renal failure (16.7%), solid tumor (13.1%),  
chronic lung diseases including bronchiectasis, sequel pulmonary tuberculosis, and 
interstitial pneumonia (13.1%), liver disease including cirrhosis or hepatitis (9.5%),  
renal transplantation (2.4%) , and other diseases (9.5%). Treatment with glucocorticoids 
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(5–40 mg/day or pulse therapy) were recorded in 31 (37.0%) patients. Total of 5 patients 
were administrated glucocorticoids concomitantly with immunosuppressant such as 
cyclosporine and azathioprine. 
 
Clinical symptoms 
In 67 patients without underlying diseases, 43 (64.2%) patients were asymptomatic 
and detected accidentally by mass screening examination. Others had pulmonary 
symptoms such as cough (n=15; 22.3%), sputum (n=4; 6.0%), chest pain (n=7; 10.4%), 
fever (n=2; 3.0%), and others. In 84 patients with underlying disease, 39 patients 
(46.4%) were asymptomatic and found by abnormal chest radiograph findings taken as 
during routine examination of underlying diseases. Others had pulmonary symptoms 
such as cough (n=15; 17.6%), sputum (n=15; 17.6%), chest pain (n=3; 3.6%), fever 
(n=20; 23.8%), and other symptoms (n=19; 22.6%). 
 
Laboratory findings 
The laboratory findings of the patients with and without underlying disease at the timing 
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of diagnosis are shown in Table 1. The patients without underlying disease are 
statistically younger, better nutrition status reflected by higher total protein and albumin 
value, compared to those with underlying diseases. Serum antigen titers (Log2[Antigen 
titer+1]) were not different statistically in both arms. 
Compared to steroid non-usage patients (n = 114), steroid usage patients (n= 36) were 
statistically significantly older (p < 0.0001), had lower lymphocyte count (p = 0.03), 
higher neutrophil count (p =0.02), lower blood serum protein (p = 0.0002), lower blood 
serum albumin (p < 0.0001), and higher CRP (p = 0.001). There was no significant 
difference in IgG, IgA, or IgM between the two groups. 
 
CT findings 
Table 2 shows the detail of CT findings between patients with or without underlying 
diseases. The CT findings of 81 of 151 pulmonary cryptococcosis patients were 
analyzed. Forty-two and 39 patients were without and with underlying diseases, 
respectively. The frequency of the four CT classification types based on predominant 
parenchymal findings and lobar distribution of the lesions is listed in Table 2. Type IIb 
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and type III lesions occurred more frequently in patients with underlying diseases than 
in those without underlying diseases. The main finding of this study is the presence of 
peripherally distributed multiple pulmonary nodules or masses with predominant lower 
lobe involvement in both patients without and with underlying diseases (P<0.0001, Data 
not shown). Parenchymal lesions in the right middle lobe (P=0.01), masses and more 
extensive lung involvement such as multiple lobes in distribution (P=0.06) were more 
common in patients with underlying disease than those without underlying diseases. The 
number of masses (>30-mm diameter) (P=0.02) and air bronchogram (P=0.05) was 
significantly more common in patients with underlying diseases than those without 
underlying diseases.  
 
Serum cryptococcal antigen titer and radiological findings 
The relationship of serum cryptococcal antigen titer and radiological findings were 
analyzed. Data from patients with meningoencephalitis was excluded. For patients with 
solitary nodules (N = 14), multiple nodules (N = 34) or consolidation (N = 8), 
comparison of the cryptococcal antigen titer (Log2[Antigen titer + 1]) revealed no 
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significant correlation between solitary and multiple nodules (N.S.); however, a 
significant higher cryptococcal antigen titer was observed in consolidation when 




The mainstay of initial treatment in both groups was azoles. Fifty-six (83.6%) patients 
without underlying diseases were initially treated with azoles, fluconazole (including 
Fos-fluconazole) (n=21, 31.3%), itraconazole (n=4, 5.9%), voriconazole (VRCZ) or 
miconazole (MCZ) (n=10, 15.0%), azoles + 5-fluorocytosine (5-FC) (n=15, 22.4%), or 
amphotericin B (n=3, 4.5%). To patients with underlying diseases, fluconazole 
(including Fos-fluconazole) (n=30, 35.7%), azoles plus 5-FC (n=17, 20.2%), 
itraconazole (n=6, 7.1%), VRCZ or MCZ (n=10, 11.9%), and amphotericin B±5-FC 
(n=4, 4.8%) were administered.  
The median duration of fluconazole (Fos-fluconazole) treatment was 90 days (range 
60–110 days) for patients without underlying disease. Five patients did not receive any 
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antifungal drugs because they were initially suspected of having lung cancer and 
underwent pneumonectomy. Three patients without underlying disease were initially 
observed without any antifungals under informed consent, as the size and number of 
radiological abnormalities were reduced spontaneously and the serum cryptococcal 
antigen titers decreased within a few months.  
Antifungal agents were administered for 6 months in all patients except three with 
refractory cryptococcosis among population with underlying diseases.  
 
Transitional serum Cryptococcal antigen titer before and after treatment 
Forty definite cases (14 cases with underlying diseases and 26 cases were without 
underlying disease) which were followed until the serum cryptococcal antigen became 
negative or up to 45 months after treatment.  
Titer changes in the latex agglutination test before and after therapy in patients 
without underlying disease and with underlying disease are depicted in Figure 2 and3, 
respectively. The mean duration of treatment for 14 patients without underlying 
diseases was 2.87 months. The cryptococcal antigen titer decreased for all cases after 
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antifungal treatment. The cryptococcal antigen became negative in 13 of 14 cases 
following administration of antifungal agents. The mean period from treatment 
cessation to negative antigen observation was 10.7 months.  
The mean duration of treatment for 26 patients with underlying diseases was 6.64 
months. In the 22 cases where antigen titers became negative after treatment, the mean 
period from treatment cessation to negative antigen observation was 13.1 months 
(Figure 3). No significant difference was observed between two groups. The serum 
antigen titers were decreased after antifungals were discontinued.  
 
Comorbid cryptococcal meningoencephalitis 
In 151 of pulmonary cryptococcosis cases, 122 patients were performed lumbar 
puncture test. Fourteen patients (9.3%) presented CNS involvement. Four and 10 
patients were without and with underlying disease, respectively (Table 3).  
Fever (57.1%; 8/14), headache (35.7%; 5/14), and appetite loss or vomiting (35.7%; 
5/14) suggesting CNS infection were observed. However, 2 patients had no CNS 
symptoms. The radiographic findings in patients with CNS involvement are shown in 
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Table 3. Solitary or multiple nodules, consolidation, reticular shadow, granular shadow 
or mixed findings were observed in meningoencephalitis patients. Pulmonary shadows 
were seen in both lungs in 7 patients. In meningoencephalitis patients, all patients 
without underlying disease were improved; however, 6 of 10 patients with underlying 
disease died. One patient did not have underlying disease; the other had a previous 
history of diabetes.  
 
Pulmonary cryptococcosis patients who died  
 Overall cryptococcal-related mortality was 9.4% (14/151). Mortality in patients with 
underlying diseases was 16.7% (14/84). No patients without underlying diseases died of 
cryptococcal-related disease. Some patients harbored underlying conditions such as 
hematologic disease and malignant tumors; the cause of death in many cases could be 
traced to worsening underlying disease. 
The radiographic finding of most of the patients who died revealed consolidation 
(57.1%; 8/14) and in both lungs (85.7%; 12/14), suggesting disseminated cryptococcal 
infection. Six of the deceased patients were diagnosed by autopsy without any 
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anti-cryptococcal treatment. The progression of serum antigen titers could not be 
observed continuously in the patients that died. Only one patient relapsed (Table. 4).  
 
Laboratory data correlated to meningoencephalitis and outcome. 
 
The clinical features including laboratory data in the patients with and without 
cryptococcal meningoencephalitis, and outcome are compared in Table 5.  
Older age, lower lymphocyte counts, higher neutrophil counts, lower serum total 
protein, lower serum albumin, low CD4/8 ratio, high CRP and higher cryptococcal 
antigen titer are related to comorbidity of meningoencephalitis. For prognosis, older age, 
higher neutrophil counts, lower serum total protein, lower serum albumin, and higher 
CRP are correlated to death. Comorbidity of meningoencephalitis and poor outcome 







 In Japan, the majority of cryptococcosis is seen in non-HIV patients. In the present 
study, we reviewed the clinical features of 151 pulmonary cryptococcosis in non-HIV 
patients in Nagasaki, Japan.  
Roughly half of the cryptococcosis patients did not have underlying diseases and 
almost half of patients (82/151, 54.3%) without respiratory symptoms were found 
accidentally by mass screening examination or routine chest X-ray check. In Japan, 
there is a unique medical insurance system which allowed people easy and cheap access 
to medical examination or annual medical check. This background may cause the 
potential bias in this study. 
It is generally recommended that HIV-negative patients with cryptococcal pneumonia 
undergo routine lumbar puncture to attempt to identify asymptomatic or subclinical 
CNS involvement that may require more potent or aggressive therapy [13]. However, 
2010 updated IDSA guidelines commented as follows, “In nonimmunocompromised 
patients with pulmonary cryptococcosis, consider a lumbar puncture to rule out 
asymptomatic CNS involvement. However, for normal hosts with asymptomatic 
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pulmonary nodule or infiltrate, no CNS symptoms, and negative or very low serum 
cryptococcal antigen, a lumbar puncture can be avoided (B-II)” [14]. Of the 14 patients 
with cryptococcal meningoencephalitis in this study, 4 did not have underlying disease. 
Six patients with meningoencephalitis were dead (eight were survived) and the 
correlation between comorbidity of meningoencephalitis and poor outcome shares same 
clinical factors. However, the possibility of existence of meningoencephalitis links 
significant poor prognosis was not evaluated due to the low number of cases. Of those, 
1 patient had solitary nodules, 1× negativity for cryptococcosis antigens, and no CNS 
disorders. We believe that the necessity of CSF examinations should be debated 
thoroughly. There has been ongoing discussion regarding the need for lumbar punctures 
in patients without CNS symptoms. The 2007 Guidelines [15] also recommend lumbar 
puncture to identify asymptomatic CNS involvement.  
 
To our knowledge, this review of pulmonary cryptococcosis constitutes the largest 
report to date describing and comparing chest CT findings in non-HIV patients both 
with and without underlying diseases. Additionally, since many cases were diagnosed 
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from mass screening check-up, it is important to investigate the unique features of 
radiological findings. Similar to recent studies of immunocompetent hosts [16-19] and 
non-AIDS individuals [20-22], the most common CT feature was the presence of 
peripherally distributed multiple pulmonary nodules or masses with predominant lower 
lobe involvement in both patients without and with underlying diseases Although the 
number of nodules or masses in previous reports has varied, there was no significant 
difference in the frequency between multiple nodules or masses (type II) and single 
lesions (type I) in our series. Multiple nodules or masses distributed in multiple lobes 
(type IIb) also tended to occur more frequently in patients with underlying diseases than 
in patients without underlying diseases.  
Cryptococcal antigen is widely recognized to have both diagnostic and prognostic 
value for cryptococcosis. Lu et al. reported on the CSF titer change in the latex 
agglutination test before and after therapy in non-HIV cryptococcal meningitis. The 
cryptococcal antigen titer in CSF decreased after therapy for every case and correlated 
with fungal clearance; however, cryptococcal antigen can remain at low titers for long 
periods after therapy, even when fungal smear and/or culture become negative. Previous 
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study suggested that the cryptococcal antigen test may not be used as an index of cure 
[23].  
In this study, serum cryptococcal antigen in pulmonary cryptococcosis patients can 
remain at low titers for long periods after therapy. However, the titers continuously 
decrease after effective therapy. Our data demonstrate that the cryptococcal antigens in 
pulmonary cryptococcosis remain detectable even months following successful therapy, 
suggesting that the cryptococcal antigen test may not be used as an index of cure or 
decision of discontinuation of treatment.  
 
The first line antifungal drugs were selected because the facilities that reported these 
cases were conducting clinical trials for antifungal drug development. Moreover, 
because the guidelines for cryptococcosis management had not yet been presented 
before 2007, azole-type drugs + 5-FC were used as pulmonary cryptococcosis treatment 
for a certain period even in patients without meningoencephalitis. 
After the 2007 Guidelines [15] was published, treatment was conducted according to 




The IDSA guideline for pulmonary cryptococcosis in non-HIV, non- 
immunosuppressed patients states that for mild-to-moderate symptoms, fluconazole 
(400 mg/day orally) should be administered for 6–12 months; persistently positive 
serum cryptococcal antigen titers are not criteria for continuance of therapy (B-II) [14].  
Conversely, the 2007 Guidelines recommend administering 400 mg/day oral 
fluconazole for 3 months for immunocompetent pulmonary cryptococcosis patients, and 
for 6 months for patients with underlying disease [15]. 
In our experience, with the exception of some severe cases, the duration of treatments 
as recommended in the 2007 Guidelines [15] appears appropriate.  
In the management of pulmonary cryptococcosis in non-HIV patients, it is important 
to confirm the presence of underlying disease and encephalomeningitis complications, 
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Table 1. Characteristics of patients with cryptococcosis with or without underlying disease 
 
  
State of underlying conditions 
  
Patients without underlying 
diseases 
Patients with underlying 
diseases Wilcoxon test 
  criteria n median IQR n median IQR p value 
1 Age 67 41 31 84 63 18.5  <0.0001 
2 lymphocyte counts 54 1985.5  573.0  74 1429.0  1218.0  0.03 
3 Neutrophil counts 55 3245.0  2403.0  75 4680.0  4273.0  0.02 
4 IgG 32 1262.0  435.0  37 1343.0  891.0  0.31 
5 IgM 32 142.0  71.3  37 145.0  96.0  0.49 
6 IgA 31 249.0  142.0  37 275.0  169.0  0.39 
7 Total protein 48 6.90  0.70  65 6.40  1.40  0.0002 
8 Serum albumin 42 4.39  0.54  60 3.60  1.29  <0.0001 
9 CD4/CD8 31 1.50  0.79  37 1.42  0.90  0.53 
10 CRP 40 0.21  0.33  49 0.84  3.60  0.001 
11 Cryptococcal antigen 56 16.00  124.00  63 32.00  252.00  0.35 
12 CD4 counts 17 874.80  282.20  19 637.00  915.20  0.99 
 




Table 2. Comparison of CT findings of cases with pulmonary cryptococcosis with or without underlying disease 
 
Patients without underlying diseases Patients with underlying diseases 
 
  n=42 % n=39 % p value 








Presence of parenchymal lesions 
     
Nodule and masses 42 100.0 39 100 
 
Consolidation 3 7.1 7 18.0 0.14 
solitary nodules/mass(type I) 14 33.3 9 23.1 0.30 
multiple nodules 25 59.5 29 74.4 0.15 
single lobe limited (type IIa) 10 23.8 5 12.8 0.06 
multiple lobe limited (type IIb) 15 35.7 24 61.5 
 
consolidation (type III) 3 7.1 7 17.9 0.14 
Distribution of parenchymal lesions 
Lobar distribution 
     
Right upper lobe 13 31.0 16 41.0 0.34 
Right middle lobe 6 14.3 15 38.5 0.01 
Right lower lobe 26 61.9 28 71.8 0.34 
Left upper lobe 10 23.8 6 15.4 0.34 
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Lingura 3 7.1 5 12.8 0.39 
Left lower lobe 20 47.6 17 43.6 0.71 
Contact with pleura 33 78.6 33 85.0 0.48 
Size(mm) 
     
 1-30 31 73.8 16 41.0 0.02 
 31- 5 11.9 11 28.0 
 
Number 
     
 1 15 35.7 11 28.0 0.85 
 2-4 10 23.8 10 26.0 
 
 5-9 7 16.7 7 18.0 
 
 10- 9 21.4 11 28.0 
 
Border 
     
 Well-defined / ill-defined 34 / 8 (81/19) 34 / 5 (87/13) 0.44 
Margin 
     
 Smooth / irregular / speculated 20 /21 / 19 (48/50/45) 12 / 27 / 20 (31/69/51) 0.25 
 Convergence of bronchi and vessel 35 83.3 31 79.0 0.65 
 Pleural identification 19 45.2 22 56.0 0.32 
Internal characteristics 
     
 Air-bronchogram 21 50.0 28 72.0 0.05 
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 Cavitation 12 28.6 16 41.0 0.24 
 Calcification 1 2.4 0 0.0 0.33 
CT halo sign 25 59.5 18 46.0 0.22 





Table 3. Summary of cases with cryptococcal meningoencephalitis 









Cr Ag Treatment Prognosis 
28 M headache solitary nodule 
rt. middle 
robe 
(-) (-) NA AMPH-B + 5-FC improved 
59 M cough, sputum consolidation both lungs (-) (-) NA 
AMPH-B + 5-FC, 
MCZ 
improved 
62 M headache, cough multiple nodules both lungs (-) (-) 512 FLCZ + 5-FC improved 
80 M 





(-) (-) 2046 FLCZ + 5-FC improved 
48 F fever, appetite loss reticular shadow both lungs SLE, NS (+) NA (-)  death 
75 F 
fever, headache, consciousness 
disorder 




60 F no symptom solitary nodule rt. lower lobe DM (-) 1 MCZ +5-FC, FLCZ  ** 
73 F 
fever, cervical lymph node 
enlargement 
** ** ATL ** 128 FLCZ+5-FC death 
61 M headache, change in personality consolidation rt. lower lobe SLE、APS (+) 1024 AMPH-B＋5-FC improved 
76 F fever, vomiting 
multiple nodules 
+ consolidation 
both lungs  DM, RA (-) NA FLCZ+5-FC improved  
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86 M fever, respiratory discomfort diffuse GGA both lungs CRF (-) 1024 F-FLCZ death 
74 F fever multiple nodules rt. lower lobe 
RA, CRF, 
amyloidosis 
(+) 1024 FLCZ+5-FC+AMPH-B death 
74 M 
fever, appetite loss, general 
fatigue 
solitary nodule lt. lower lobe 
Wegener ‘s 
granulomatosis  
(+) 256 FLCZ+5-FC improved 
60 M appetite loss, general fatigue multiple nodules both lungs ATL, DM (+) NA FLCZ+5-FC death 
 
ATL, Adult T cell leukemia; SLE, systemic lupus erythematosus; NS, nephrosis syndrome; DM, diabetes mellitus; RA, rheumatoid 
arthritis; CRF, chronic renal failure; APS, anti-phospholipid antibody syndrome, rt., right, and lt., left; Cr Ag, Cryptococcal antigen titer; 
NA, not available. AMPH-B, amphotericin B; 5-FC, flucytosine; FLCZ, fluconazole; F-FLCZ, fos-fluconazole; MCZ, miconazole. 















Treatment Meningoencephalitis Diagnostic methods 








AMPH-B＋5FC , ITZ, 
FLCZ 
(-) TBLB 
64 F consolidation   both lungs ATL (-) FLCZ (+) sputum culture 
69 F consolidation   rt. upper lobe LK (+) FLCZ+5FC not done BALF culture 
86 M diffuse GGA both lungs CRF (-) F-FLCZ (+) 
sputum, CSF, Urine, 
blood culture 
48 F reticular shadow both lungs SLE, NS (+) (-) (+)* autopsy  
75 F consolidation   both lungs Bladder tumor (-) (-) (-) autopsy  
62 F consolidation   both lungs PN, ARF (+) FLCZ, MCZ (-) autopsy  
75 F granular shadow both lungs ATL (-) (-) (+)* autopsy  







both lungs IP (+) (-) not done autopsy  
73 F consolidation   both lungs ATL ** FLCZ+5-FC not done sputum culture 




(+) FLCZ+5-FC+AMPH-B (+) 
BALF, CSF, blood 
culture 
60 M multiple nodules both lungs ATL, DM (+) FLCZ+5-FC (+) 
BALF, CSF, blood, 
prostatic fluid culture 
GGA, ground-glass attenuation; rt., right; ML, malignant lymphoma; DM, diabetes mellitus; LC, liver cirrhosis; ATL, adult T cell 
leukemia; HCC, hepatocellular carcinoma; LK, lung cancer; CRF, chronic renal failure; SLE, systemic lupus erythematosus; NS, 
nephrosis syndrome; PN, polyarteritis nodosa; ARF, acute renal failure; RA, rheumatoid arthritis; TB, tuberculosis; IP, interstitial 
pneumonia; TBLB, transbronchial biopsy; BALF, bronchial alveolar lavage fluid, and CSF, cerebrospinal fluid. AMPH-B, amphotericin 
B; 5-FC, flucytosine; FLCZ, fluconazole; ITZ, itraconazole; F-FLCZ, fos fluconazole; MCZ, miconazole. 





Table 5. Comparison of clinical characters of patients with or without cryptococcal meningoencephalitis and prognosis 
 
    Comorbid Meningoencephalitis Prognosis 






test improved Died 
Wilcoxon 
test 
  criteria n median IQR n median IQR p value n median IQR n median IQR p value 
1 Age 110 54.5  30.0  14 67.5  15.0  0.004 123 55.0  30.0  13 69.0  13.0  0.004 
2 lymphocyte counts 98 1914.0  1006.0  11 1023.0  926.0  0.005 108 1874.0  992.5  11 1370.0  2792.0  0.26 
3 Neutrophil counts 99 3355.0  2658.0  11 7626.0  4280.0  0.001 109 3780.0  2780.0  11 7832.0  4908.0  0.003 
4 IgG 61 1290.0  661.0  5 1140.0  468.0  0.78  63 1307.0  600.0  5 1343.0  694.0  0.87  
5 IgM 61 142.0  79.0  5 103.0  115.3  0.33  63 142.0  81.0  5 157.0  115.3  0.80  
6 IgA 60 259.0  179.0  5 328.0  133.0  0.74 62 259.0  167.0  5 454.0  256.0  0.34 
7 Total protein 88 6.90  0.90  11 5.90  1.50  0.02 99 6.90  0.90  10 5.30  0.50  0.0003 
8 Serum albumin 82 4.10  0.80  9 3.10  1.60  0.01 90 4.10  0.80  8 2.65  1.13  0.0006 
9 CD4/CD8 60 1.47  0.74  3 0.96  0.43  0.03 61 1.45  0.72  5 1.34  0.85  0.45 
10 CRP 69 0.26  1.02  4 10.59  13.44  0.004 76 0.29  1.08  5 4.12  12.29  0.003 
11 Cryptococcal antigen 90 16.00  120.00  7 1024.00  1920.00  0.02 103 16.00  252.00  11 128.00  1016.00  0.15 
12 CD4 counts 30 719.50  474.60  1 421.50    0.30  34 734.60  480.80  1 95.00    0.09 
 




Figure 1. The relationship of serum cryptococcal antigen titer and radiological findings. 
The morphological characteristics were classified as solitary nodule/mass (type I), 
multiple nodules/masses (type II), and consolidation (type III). Cryptococcal antigen 
titers were transformed to the logarithm to the base 2 (Log2[Ag + 1]). Data from 
patients with meningoencephalitis was excluded. 
 
Figure 2. Transitional change of the latex agglutination test after treatment in patients 
without underlying diseases. Solid line indicates the duration of treatment and dotted 
line indicates the following time after treatment. The mean duration of treatment for 14 
patients without underlying diseases was 2.87 months. The cryptococcal antigen titer 
decreased for all cases after antifungal treatment. The cryptococcal antigen became 
negative in 13 of 14 cases following administration of antifungal agents. The mean 
period from treatment cessation to negative antigen observation was 10.7 months. The 
patients were followed until the serum antigen become negative or up to 45 months  
 
Figure 3. Transitional change of the latex agglutination test after treatment in patients 
with underlying diseases. Solid lines and dotted lines denote treatment duration and 
duration of follow-up after treatment, respectively. The mean duration of treatment for 
26 patients with underlying diseases was 6.64 months. In the 22 cases where antigen 
titers became negative after treatment, the mean period from treatment cessation to 
negative antigen observation was 13.1 months. The patients were followed until the 
serum antigen become negative or up to 45 months  
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Figure 3. Transitional change of the latex agglutination test after treatment in patients with underlying diseases
(months)
